A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.
Also called NCT01153815
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 170 participants
- Sponsor
- Registry
-
NCT01153815
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01153815. Randomized; quadruple masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2012-05-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
- Condition
- Cerebrovascular Accident
- Intervention (Drug)
- GSK1358820(Botulinum toxin type A)
- Intervention (Drug)
- placebo
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct01153815- Content hash
2a3dc6d8908e2092db0acc96b1653458eca7fae52fdc7c41d5b823c6659830c6